| 代谢组学在乳腺癌诊疗中应用的研究进展 |
| 投稿时间：2021-09-24 修订日期：2022-07-19 点此下载全文 |
| 引用本文：马小雨,罗彩萍,刘悦.代谢组学在乳腺癌诊疗中应用的研究进展[J].药学实践杂志,2023,41(3):139~145 |
| 摘要点击次数: 823 |
| 全文下载次数: 807 |
|
| 基金项目:上海市科学技术委员会“启明星”项目（21QA1411600） |
|
| 中文摘要:乳腺癌（BC）是发病率较高的恶性肿瘤性疾病，发现时常处于晚期、预后较差，由于缺乏准确的生物标志物，乳腺癌的早期诊断及治疗仍不理想。代谢组学（metabolomics）是一门采用高通量分析技术来研究机体在不同病理生理刺激或基因突变影响下内源性代谢物动态变化规律的新学科，为乳腺癌生物标志物的筛选、疾病诊疗提供了新途径。主要概述代谢组学并介绍其在乳腺癌早期诊断、药效评价、疾病预后中应用的研究进展。 |
| 中文关键词:代谢组学 乳腺癌 生物标志物 早期诊断 药效评价 疾病预后 |
| |
| Application of metabonomics in breast cancer |
|
|
| Abstract:Breast cancer is a kind of malignant tumor discovered lately, with a high incidence and a poor prognosis. The shortage of relevant biological biomarkers lead to the unsatisfactory treatment efficacy and the early diagnosis in breast cancer. Metabolomics is a new discipline that uses high-throughput analysis techniques to study the dynamic changes of endogenous metabolites under the influence of different pathological physiological stimulation or gene mutations, which has provided a novel way for biomarker screening and disease diagnosis and treatment. The overview of metabolomics and its applications in breast cancer early diagnosis, drug efficacy evaluation, and disease prognosis were summarized in this review. |
| keywords:metabolomics breast cancer biological biomarkers early diagnosis drug efficacy evaluation disease prognosis |
| 查看全文 查看/发表评论 下载PDF阅读器 |
|
| 关闭 |
